ATE311464T1 - Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen - Google Patents
Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungenInfo
- Publication number
- ATE311464T1 ATE311464T1 AT01956747T AT01956747T ATE311464T1 AT E311464 T1 ATE311464 T1 AT E311464T1 AT 01956747 T AT01956747 T AT 01956747T AT 01956747 T AT01956747 T AT 01956747T AT E311464 T1 ATE311464 T1 AT E311464T1
- Authority
- AT
- Austria
- Prior art keywords
- cell
- therapeutic
- activated receptors
- diagnostic uses
- targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL13741900A IL137419A0 (en) | 2000-07-20 | 2000-07-20 | Nk cells activating receptors and their therapeutic and diagnostic uses |
PCT/IL2001/000664 WO2002008287A2 (en) | 2000-07-20 | 2001-07-19 | Nk cells activating receptors and their therapeutic and diagnostic uses |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE311464T1 true ATE311464T1 (de) | 2005-12-15 |
Family
ID=11074420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01956747T ATE311464T1 (de) | 2000-07-20 | 2001-07-19 | Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040072256A1 (de) |
EP (1) | EP1301605B1 (de) |
JP (1) | JP2004504065A (de) |
AT (1) | ATE311464T1 (de) |
AU (2) | AU2001278662B2 (de) |
CA (1) | CA2416733A1 (de) |
DE (1) | DE60115452D1 (de) |
IL (1) | IL137419A0 (de) |
WO (1) | WO2002008287A2 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071314B2 (en) * | 2001-12-14 | 2011-12-06 | President And Fellows Of Harvard College | Immunocellular receptors related to neurological disorders and therapeutic uses thereof |
EP1581169A4 (de) * | 2002-11-08 | 2008-09-17 | Genentech Inc | Zusammensetzungen und verfahren zurbehandlung von erkrankungen in verbindung mit natürlichen killerzellen |
WO2004053054A2 (en) * | 2002-12-09 | 2004-06-24 | Natspears Ltd. | Nk cell receptor conjugates for treating malignancies |
EP1445614A1 (de) * | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Verfahren zur in vitro Überwachung der Entwicklung von HIV Virus eines Individuums |
WO2005076001A2 (en) * | 2004-02-06 | 2005-08-18 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual |
GB0305478D0 (en) | 2003-03-10 | 2003-04-16 | Bioxell Spa | Diagnostic and prognostic compounds and method |
WO2005000086A2 (en) | 2003-06-30 | 2005-01-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS |
WO2005051973A2 (en) * | 2003-11-25 | 2005-06-09 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Peptides derived from natural cytotoxicity receptors and methods of use thereof |
WO2006103569A2 (en) * | 2005-03-18 | 2006-10-05 | Innate Pharma | Expression vectors and methods for obtaining nk cell specific expression |
US7932055B2 (en) * | 2006-06-22 | 2011-04-26 | Novo Nordisk A/S | Soluble heterodimeric CD94/NKG2 receptors fusion proteins |
WO2007147901A1 (en) * | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
US9593376B2 (en) | 2008-06-02 | 2017-03-14 | Institut Gustave Roussy | Natural killer p30 (NKp30) dysfunction and the biological applications thereof |
DK2408468T3 (da) | 2009-03-19 | 2014-07-21 | Yissum Res Dev Co | Anvendelse af NKp46 til forebyggelse af type 1-diabetes |
WO2012175613A1 (en) | 2011-06-21 | 2012-12-27 | Innate Pharma | NKp46-MEDIATED NK CELL TUNING |
WO2013140393A1 (en) | 2012-03-21 | 2013-09-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Peptides derived from the d1 - domain of nkp46 |
CN106102776B (zh) | 2014-01-24 | 2020-02-14 | 圣安德鲁斯大学董事会 | 免疫调节化合物 |
EP3433281A1 (de) * | 2016-03-21 | 2019-01-30 | Elstar Therapeutics, Inc. | Multispezifische und multifunktionelle moleküle und verwendungen davon |
CN109689086A (zh) | 2016-07-11 | 2019-04-26 | 国家生物技术研究所公司 | 具有延长的血清半衰期的融合蛋白 |
GB201616009D0 (en) | 2016-09-20 | 2016-11-02 | Univ Court Of The Univ Of St Andrews The | Treatment and/or prevention of sepsis |
GB201616007D0 (en) | 2016-09-20 | 2016-11-02 | Univ Court Of The Univ Of St Andrews The | Novel Adjuvants |
GB201616006D0 (en) | 2016-09-20 | 2016-11-02 | Univ Court Of The Univ Of St Andrews The | Cell modulation |
CN116964099A (zh) * | 2021-03-05 | 2023-10-27 | 上海齐鲁制药研究中心有限公司 | 针对NKp46的抗体及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5912170A (en) * | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
US5641863A (en) * | 1993-09-30 | 1997-06-24 | University Of Pennsylvania | Chimeric IgG Fc receptors |
DE69634855T2 (de) * | 1995-02-24 | 2006-05-18 | The General Hospital Corp., Boston | Neuorientierung der zellulären immunität durch rezeptorchimären |
CA2217020A1 (en) * | 1995-05-16 | 1996-11-21 | Bristol-Myers Squibb Company | Recombinant heregulins and their biological functions upon receptor activation |
ZA9810133B (en) * | 1997-11-07 | 1999-05-17 | Biogen Inc | BMOG a novel protein member of the myelin-oligodendrocyte glycoprotein family and its use for ummonomodulatory purposes |
-
2000
- 2000-07-20 IL IL13741900A patent/IL137419A0/xx unknown
-
2001
- 2001-07-19 AU AU2001278662A patent/AU2001278662B2/en not_active Ceased
- 2001-07-19 AU AU7866201A patent/AU7866201A/xx active Pending
- 2001-07-19 JP JP2002514191A patent/JP2004504065A/ja not_active Abandoned
- 2001-07-19 US US10/333,481 patent/US20040072256A1/en not_active Abandoned
- 2001-07-19 DE DE60115452T patent/DE60115452D1/de not_active Expired - Lifetime
- 2001-07-19 EP EP01956747A patent/EP1301605B1/de not_active Expired - Lifetime
- 2001-07-19 WO PCT/IL2001/000664 patent/WO2002008287A2/en active IP Right Grant
- 2001-07-19 CA CA002416733A patent/CA2416733A1/en not_active Abandoned
- 2001-07-19 AT AT01956747T patent/ATE311464T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2001278662B2 (en) | 2006-09-28 |
WO2002008287A2 (en) | 2002-01-31 |
IL137419A0 (en) | 2001-07-24 |
WO2002008287A3 (en) | 2002-12-19 |
CA2416733A1 (en) | 2002-01-31 |
DE60115452D1 (de) | 2006-01-05 |
EP1301605B1 (de) | 2005-11-30 |
AU7866201A (en) | 2002-02-05 |
JP2004504065A (ja) | 2004-02-12 |
US20040072256A1 (en) | 2004-04-15 |
EP1301605A2 (de) | 2003-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE311464T1 (de) | Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen | |
CY1111193T1 (el) | Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους | |
ES2562651T3 (es) | Lixisenatida para el uso en el tratamiento de la estenosis o/y la obstrucción del sistema de conductos pancreáticos | |
DE602005026789D1 (de) | Le | |
UY29504A1 (es) | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. | |
CO5611160A2 (es) | Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos | |
CY1115212T1 (el) | Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44 | |
BRPI0821110B8 (pt) | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo | |
BR0011838B1 (pt) | elemento de sela e estrutura de misturador estático. | |
NO20054078D0 (no) | Humane antistoffer spesifikke for Interleukin 15 (IL15). | |
AR055223A1 (es) | Caracterizacion y compensacion de electrodos del ecg | |
DE60032486D1 (de) | Prion protein peptide und deren verwendung | |
RU94045826A (ru) | Моноклональные антитела против рецептора интерферона, с нейтрализующим действием против интерферона типа i | |
NO20024932D0 (no) | Kontrastmiddel | |
DE602006019977D1 (de) | Therapie mit anti-cd4-antikörpern und bestrahlung | |
AR058173A1 (es) | Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas | |
DOP2009000208A (es) | Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana | |
EP1667716B8 (de) | Zytotoxizitätsmediation in zellen die auf eine oberflächenexpression von cd44 hinweisen | |
HUP0301812A2 (hu) | Átvizsgálási (screening) eljárás | |
ATE466595T1 (de) | Verbindungen und methoden für das downregulating der effekte von tgf-beta | |
ATE449847T1 (de) | Hepatitis c rezeptorprotein cd81 | |
ATE395363T1 (de) | Monoklonale antikörper gegen das protein g3bp und deren verwendungen | |
DE60141297D1 (de) | Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper | |
NO20050216L (no) | Steroidkonjugater samt fremstilling og anvendelse derav | |
ATE444081T1 (de) | Proteine-abgabe durch polare epithelzellen schichte |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |